We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review.

We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

We'll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we'll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we'll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer